Nestle is seeking to turn the rise of GLP-1 weight-loss drugs from a threat into a business opportunity, using artificial intelligence and nutritional science to develop products aimed at millions of consumers taking medicines such as Ozempic and Wegovy.

Nestle’s Response

The company believes the drugs are also creating a new market for products designed to address the side effects of rapid weight loss. Chief Technology Officer Stefan Palzer told Reuters that Nestle was using AI and other technology to analyze clinical research, identify nutrient combinations, and develop products tailored to GLP-1 users.

Nestle has begun adding collagen protein to products under its Vital Proteins brand to address concerns around skin, hair, and nail health linked to rapid weight loss. The company has also patented combinations of proprietary ingredients designed to reduce appetite among consumers who often experience increased hunger after discontinuing GLP-1 treatments.

Tackling Side Effects

Nestle’s scientists have been studying the consequences of rapid weight loss and developing products designed to help consumers manage them. The company is using AI tools to process large volumes of clinical research and identify combinations of nutrients that may help support muscle health, hydration, and nutritional intake.

Nestle has already launched products aimed at GLP-1 users, including Boost Advanced Nutrition Shake, marketed as containing 35 grams of protein to support muscle health during weight loss. In Asia and Australia, Nestle has introduced a higher-protein version of its Milo malt drink called Milo PRO High Protein.

Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.